| Study of ALXN1850 in Participants With Hypophosphatasia (HPP) (NCT04980248) | Alexion Pharmaceuticals, Inc. | 2021-09-28 |
| United States Hypophosphatasia Molecular Research Center (NCT05062629) | Children's Mercy Hospital Kansas City | 2021-08-24 |
| The PORTRAIT Study (NCT04222452) | Sheffield Teaching Hospitals NHS Foundation Trust | 2021-07-12 |
| Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due to Chronic Disease (NCT04189315) | Alexion Pharmaceuticals, Inc. | 2020-04-01 |
| Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa) (NCT04195763) | Alexion Pharmaceuticals, Inc. | 2019-11-06 |
| Early Check: Expanded Screening in Newborns (NCT03655223) | RTI International | 2018-10-15 |
| Circulating miRNAs and Bone Microstructure in Adults With Hypophosphatasia (NCT04018287) | Medical University of Vienna | 2017-08-01 |
| Characterisation of Adult-Onset Hypophosphatasia (NCT02796885) | Sheffield Teaching Hospitals NHS Foundation Trust | 2016-11-01 |
| Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP) (NCT02797821) | Alexion Pharmaceuticals, Inc. | 2016-06-06 |
| Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan (NCT02531867) | Alexion Pharmaceuticals, Inc. | 2015-06-01 |
| Burden of Disease in Hypophosphatasia (HPP) (NCT02291497) | Wuerzburg University Hospital | 2014-10-01 |
| Natural History Study of Patients With Hypophosphatasia (HPP) (NCT02237625) | Duke University | 2014-09-01 |
| Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patients With Juvenile-onset HPP Who Served as Historical Controls in ENB-006-09 (NCT02235493) | Alexion Pharmaceuticals, Inc. | 2014-08-01 |
| Safety and Efficacy of Asfotase Alfa in Patients With Hypophosphatasia (HPP) (NCT02456038) | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | 2014-08-01 |
| Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP) (NCT01406977) | Ultragenyx Pharmaceutical Inc | 2011-07-01 |
| Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (NCT01793168) | Sanford Health | 2010-07-01 |
| Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP) (NCT01176266) | Alexion Pharmaceuticals, Inc. | 2010-07-01 |
| Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP) (NCT01163149) | Alexion Pharmaceuticals, Inc. | 2010-06-01 |
| Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP) (NCT00894075) | Alexion Pharmaceuticals, Inc. | 2009-07-01 |
| Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP) (NCT01205152) | Alexion Pharmaceuticals, Inc. | 2009-04-01 |
| Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP) (NCT02496689) | Alexion Pharmaceuticals, Inc. | |